These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 35400291)

  • 1. The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center.
    Ellithi M; Abdallah M; Fischer M; Ailts I; Fanta J; Waligoske K; Bell M; Nelson ME; Bleeker J
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):479-486. PubMed ID: 35400291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
    Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
    Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
    Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
    J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
    Gueiderikh A; Tarabay A; Abdelouahab M; Smolenschi C; Tanguy ML; Valery M; Malka D; Pudlarz T; Fuerea A; Boige V; Hollebecque A; Ducreux M; Boilève A
    BMC Cancer; 2024 Feb; 24(1):272. PubMed ID: 38408958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World.
    King G; Ittershagen S; He L; Shen Y; Li F; Villacorta R
    Adv Ther; 2022 Dec; 39(12):5433-5452. PubMed ID: 36197644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
    Rochefort P; Lardy-Cleaud A; Sarabi M; Desseigne F; Cattey-Javouhey A; de la Fouchardière C
    Oncologist; 2019 Dec; 24(12):1543-1548. PubMed ID: 31164454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.
    Wang S; Bager CL; Karsdal MA; Chondros D; Taverna D; Willumsen N
    J Transl Med; 2021 Jan; 19(1):39. PubMed ID: 33478521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma.
    Varzaru B; Iacob RA; Croitoru AE; Iacob SM; Radu CE; Dumitrescu SM; Gheorghe C
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer.
    De Luca R; Blasi L; Alù M; Gristina V; Cicero G
    Drug Des Devel Ther; 2018; 12():1769-1775. PubMed ID: 29950811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.
    Yu KH; Ozer M; Cockrum P; Surinach A; Wang S; Chu BC
    Cancer Med; 2021 Dec; 10(24):8934-8943. PubMed ID: 34811961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
    Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
    Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
    Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
    Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
    Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
    Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.